Categories
Life Sciences Consumer Goods Materials and Chemicals Construction & Manufacturing Food and Beverages Energy and Power Semiconductor and Electronics Automotive and Transportation ICT & Media Aerospace & Defense BFSI

Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com

Amylin Analogs Market by Diabetes Type (Type I Diabetes  , Type II Diabetes  , Gestational Diabetes) and by End User (Hospitals, Drug Stores, Pharmacy Stores, Online Pharmacy, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032

A12460

Pages: NA

Charts: NA

Tables: NA

Amylin Analogs Market Outlook 2030:

Amylin is basically a peptide hormone that is inducted with pancreatic beta-cell and is thus deficient in diabetic population. The hormone acts as a satiety agent while delaying gastric emptying. It also assists the insulin in controlling post meal high glucose levels Amylin Analogs are thus injectable drugs used to treat both Type-I and Type-II diabetes. Advantages of using the drug include low blood sugar levels, weight loss, enhanced digestion and suppression in the release of glucagon from the stomach. However, there are a few side effects associated with the usage of amylin analogs including vomiting, nausea and heart burn. Some of the major amylin analogs are pramlintide, smylin, etc.

Amylin analogs market is segmented based on type of diabetes such Type I and Type II diabetes with Asia Pacific witnessing higher number of cases of the later and North America topping the former. With regards to end users, hospitals and pharmacy stores top the list owing to being avenues for highest sales. Lately, owing to COVID-19 restrictions and overall move towards ecommerce, online pharmacy sales have shot up significantly too.

COVID-19 Impact Analysis

Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as Hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing shortage of these drugs. Thus, the pharmaceutical and biotechnology industry is expected to witness a significant growth in the future owing to the demand for vaccine and treatment drugs for COVID-19. This in turn is expected to have a significant impact on the amylin analogs market.

Top Impacting Factors

  • Growing burden of diabetes on the industrialized economies around the world with their role as global players and the subsequent need of advanced therapeutic drugs towards its treatment is a major factor driving growth of amylin analogs market.
  • Impending unmet needs regarding advancements in healthcare infrastructure in high populace economies like India and China which experience higher diabetic population is another factor driving inception of new players in the industry and growth in overall amylin analogs market share.
  • Increasing number of awareness initiatives regarding diabetes, its types, causes and treatment by governments across the globe is yet another factor driving the amylin analogs market growth.
  • Shift of public policies towards developing enhanced healthcare supply chains owing to COVID-19 is prompting frequent product developments and clinical trials. This in turn is anticipated to affect amylin analogs market as well.
  • Adoption of ecommerce as an alternative to traditional pharmacy stores during times of COVID-19 and beyond is likely to increase sales of amylin analogs as Omni channel strategy holds the capability to provide the customer base with beyond expectation service levels.
  • However, higher cost of development and distribution associated with the drug is likely to hamper growth especially in rogue nations with less support from the ruling government.

Key Market Trends

  • North America is likely to retain its position as the market leader when it comes to amylin analogs owing to higher proportion of diabetic patients combined with higher levels of disposable income, higher awareness and basic healthcare facilities at the disposal.
  • Amylin analogs market is forecasted to increase two fold in Asia Pacific region in the next 1- years owing to rise in demand from Type I diabetic population residing in the region coupled with advancements in analog technology through massive collaborations between regional players such as Hindanol, etc.
  • Recently, Novo Novardisk announced their new amylin analog product by the name of Rybelsus towards treatment of Type-2 diabetic patients.
  • In 2019, Novo Novardisk also announced opening of a new amylin analog manufacturing facility in Kalundborg, Denmark for rapid penetration into North European market.
  • Research and development is also underway regarding development of long term solution for treatment of diabetes. This includes development of artificial pancreas with the idea gaining rapid popularity owing to support from United States Food and Drug Administration (USFDA)

Key Benefits of the Report

  • This study presents the analytical depiction of the amylin analogs industry along with the current trends and future estimations to determine the imminent investment pockets.
  • The report presents information related to key drivers, restraints, and opportunities along with a detailed analysis of the amylin analogs market share.
  • The current market is quantitatively analyzed to highlight the amylin analogs  growth scenario.
  • Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
  • The report provides a detailed analysis depending on competitive intensity and how the competition will take shape in the coming years.

Questions Answered in the Amylin Analogs Report

  • Which are the leading players active in the amylin analogs market?
  • How is each segment of the market expected to grow during the forecast period?
  • What are the adoption trends for the amylin analogs market in emerging economies and established economies across the world?
  • What are the current trends that will influence the market in the next few years?
  • What are the driving factors, restraints, and opportunities of the market?
  • What future projections would help in taking further strategic steps?
  • What are the impacts of COVID-19 in the industry?
  • What is amylin analogs?
  • What is the amylin analogs  market prediction in the future?
  • What are the current trends and predicted trends?

 Key Market Segments

  • By Diabetes Type
    • Type I Diabetes  
    • Type II Diabetes  
    • Gestational Diabetes
  • By End User
    • Hospitals
    • Drug Stores
    • Pharmacy Stores
    • Online Pharmacy
    • Others
  • By Region
    • North America
      • U.S.
      • Canada
      • Mexico
    • Europe
      • France
      • Germany
      • Italy
      • Spain
      • UK
      • Rest of Europe
    • Asia-Pacific
      • China
      • Japan
      • India
      • South Korea
      • Australia
      • Rest of Asia-Pacific
    • LAMEA
      • Brazil
      • South Africa
      • Saudi Arabia
      • Rest of LAMEA

 
Key Market Players

  • Boehringer Ingelheim
  • Novo Nordisk
  • Sanofi
  • Victoza
  • Jardiance Ltd.
  • Soliqua
  • Trulicity
  • Lantus
  • AstraZeneca
  • Eli Lilly and Company

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

  • CHAPTER 4: AMYLIN ANALOGS MARKET, BY DIABETES TYPE

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Diabetes Type

    • 4.2. Type I Diabetes  

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Type II Diabetes  

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

    • 4.4. Gestational Diabetes

      • 4.4.1. Key Market Trends, Growth Factors and Opportunities

      • 4.4.2. Market Size and Forecast, By Region

      • 4.4.3. Market Share Analysis, By Country

  • CHAPTER 5: AMYLIN ANALOGS MARKET, BY END USER

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By End User

    • 5.2. Hospitals

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Drug Stores

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

    • 5.4. Pharmacy Stores

      • 5.4.1. Key Market Trends, Growth Factors and Opportunities

      • 5.4.2. Market Size and Forecast, By Region

      • 5.4.3. Market Share Analysis, By Country

    • 5.5. Online Pharmacy

      • 5.5.1. Key Market Trends, Growth Factors and Opportunities

      • 5.5.2. Market Size and Forecast, By Region

      • 5.5.3. Market Share Analysis, By Country

    • 5.6. Others

      • 5.6.1. Key Market Trends, Growth Factors and Opportunities

      • 5.6.2. Market Size and Forecast, By Region

      • 5.6.3. Market Share Analysis, By Country

  • CHAPTER 6: AMYLIN ANALOGS MARKET, BY REGION

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By Region

    • 6.2. North America

      • 6.2.1. Key Market Trends and Opportunities

      • 6.2.2. Market Size and Forecast, By Diabetes Type

      • 6.2.3. Market Size and Forecast, By End User

      • 6.2.4. Market Size and Forecast, By Country

      • 6.2.5. U.S. Amylin Analogs Market

        • 6.2.5.1. Market Size and Forecast, By Diabetes Type
        • 6.2.5.2. Market Size and Forecast, By End User

      • 6.2.6. Canada Amylin Analogs Market

        • 6.2.6.1. Market Size and Forecast, By Diabetes Type
        • 6.2.6.2. Market Size and Forecast, By End User

      • 6.2.7. Mexico Amylin Analogs Market

        • 6.2.7.1. Market Size and Forecast, By Diabetes Type
        • 6.2.7.2. Market Size and Forecast, By End User

    • 6.3. Europe

      • 6.3.1. Key Market Trends and Opportunities

      • 6.3.2. Market Size and Forecast, By Diabetes Type

      • 6.3.3. Market Size and Forecast, By End User

      • 6.3.4. Market Size and Forecast, By Country

      • 6.3.5. France Amylin Analogs Market

        • 6.3.5.1. Market Size and Forecast, By Diabetes Type
        • 6.3.5.2. Market Size and Forecast, By End User

      • 6.3.6. Germany Amylin Analogs Market

        • 6.3.6.1. Market Size and Forecast, By Diabetes Type
        • 6.3.6.2. Market Size and Forecast, By End User

      • 6.3.7. Italy Amylin Analogs Market

        • 6.3.7.1. Market Size and Forecast, By Diabetes Type
        • 6.3.7.2. Market Size and Forecast, By End User

      • 6.3.8. Spain Amylin Analogs Market

        • 6.3.8.1. Market Size and Forecast, By Diabetes Type
        • 6.3.8.2. Market Size and Forecast, By End User

      • 6.3.9. UK Amylin Analogs Market

        • 6.3.9.1. Market Size and Forecast, By Diabetes Type
        • 6.3.9.2. Market Size and Forecast, By End User

      • 6.3.10. Russia Amylin Analogs Market

        • 6.3.10.1. Market Size and Forecast, By Diabetes Type
        • 6.3.10.2. Market Size and Forecast, By End User

      • 6.3.11. Rest Of Europe Amylin Analogs Market

        • 6.3.11.1. Market Size and Forecast, By Diabetes Type
        • 6.3.11.2. Market Size and Forecast, By End User

    • 6.4. Asia-Pacific

      • 6.4.1. Key Market Trends and Opportunities

      • 6.4.2. Market Size and Forecast, By Diabetes Type

      • 6.4.3. Market Size and Forecast, By End User

      • 6.4.4. Market Size and Forecast, By Country

      • 6.4.5. China Amylin Analogs Market

        • 6.4.5.1. Market Size and Forecast, By Diabetes Type
        • 6.4.5.2. Market Size and Forecast, By End User

      • 6.4.6. Japan Amylin Analogs Market

        • 6.4.6.1. Market Size and Forecast, By Diabetes Type
        • 6.4.6.2. Market Size and Forecast, By End User

      • 6.4.7. India Amylin Analogs Market

        • 6.4.7.1. Market Size and Forecast, By Diabetes Type
        • 6.4.7.2. Market Size and Forecast, By End User

      • 6.4.8. South Korea Amylin Analogs Market

        • 6.4.8.1. Market Size and Forecast, By Diabetes Type
        • 6.4.8.2. Market Size and Forecast, By End User

      • 6.4.9. Australia Amylin Analogs Market

        • 6.4.9.1. Market Size and Forecast, By Diabetes Type
        • 6.4.9.2. Market Size and Forecast, By End User

      • 6.4.10. Thailand Amylin Analogs Market

        • 6.4.10.1. Market Size and Forecast, By Diabetes Type
        • 6.4.10.2. Market Size and Forecast, By End User

      • 6.4.11. Malaysia Amylin Analogs Market

        • 6.4.11.1. Market Size and Forecast, By Diabetes Type
        • 6.4.11.2. Market Size and Forecast, By End User

      • 6.4.12. Indonesia Amylin Analogs Market

        • 6.4.12.1. Market Size and Forecast, By Diabetes Type
        • 6.4.12.2. Market Size and Forecast, By End User

      • 6.4.13. Rest of Asia Pacific Amylin Analogs Market

        • 6.4.13.1. Market Size and Forecast, By Diabetes Type
        • 6.4.13.2. Market Size and Forecast, By End User

    • 6.5. LAMEA

      • 6.5.1. Key Market Trends and Opportunities

      • 6.5.2. Market Size and Forecast, By Diabetes Type

      • 6.5.3. Market Size and Forecast, By End User

      • 6.5.4. Market Size and Forecast, By Country

      • 6.5.5. Brazil Amylin Analogs Market

        • 6.5.5.1. Market Size and Forecast, By Diabetes Type
        • 6.5.5.2. Market Size and Forecast, By End User

      • 6.5.6. South Africa Amylin Analogs Market

        • 6.5.6.1. Market Size and Forecast, By Diabetes Type
        • 6.5.6.2. Market Size and Forecast, By End User

      • 6.5.7. Saudi Arabia Amylin Analogs Market

        • 6.5.7.1. Market Size and Forecast, By Diabetes Type
        • 6.5.7.2. Market Size and Forecast, By End User

      • 6.5.8. UAE Amylin Analogs Market

        • 6.5.8.1. Market Size and Forecast, By Diabetes Type
        • 6.5.8.2. Market Size and Forecast, By End User

      • 6.5.9. Argentina Amylin Analogs Market

        • 6.5.9.1. Market Size and Forecast, By Diabetes Type
        • 6.5.9.2. Market Size and Forecast, By End User

      • 6.5.10. Rest of LAMEA Amylin Analogs Market

        • 6.5.10.1. Market Size and Forecast, By Diabetes Type
        • 6.5.10.2. Market Size and Forecast, By End User

  • CHAPTER 7: COMPETITIVE LANDSCAPE

    • 7.1. Introduction

    • 7.2. Top Winning Strategies

    • 7.3. Product Mapping Of Top 10 Player

    • 7.4. Competitive Dashboard

    • 7.5. Competitive Heatmap

    • 7.6. Top Player Positioning, 2024

  • CHAPTER 8: COMPANY PROFILES

    • 8.1. Novo Nordisk

      • 8.1.1. Company Overview

      • 8.1.2. Key Executives

      • 8.1.3. Company Snapshot

      • 8.1.4. Operating Business Segments

      • 8.1.5. Product Portfolio

      • 8.1.6. Business Performance

      • 8.1.7. Key Strategic Moves and Developments

    • 8.2. Sanofi

      • 8.2.1. Company Overview

      • 8.2.2. Key Executives

      • 8.2.3. Company Snapshot

      • 8.2.4. Operating Business Segments

      • 8.2.5. Product Portfolio

      • 8.2.6. Business Performance

      • 8.2.7. Key Strategic Moves and Developments

    • 8.3. AstraZeneca

      • 8.3.1. Company Overview

      • 8.3.2. Key Executives

      • 8.3.3. Company Snapshot

      • 8.3.4. Operating Business Segments

      • 8.3.5. Product Portfolio

      • 8.3.6. Business Performance

      • 8.3.7. Key Strategic Moves and Developments

    • 8.4. Boehringer Ingelheim

      • 8.4.1. Company Overview

      • 8.4.2. Key Executives

      • 8.4.3. Company Snapshot

      • 8.4.4. Operating Business Segments

      • 8.4.5. Product Portfolio

      • 8.4.6. Business Performance

      • 8.4.7. Key Strategic Moves and Developments

    • 8.5. Eli Lilly And Company

      • 8.5.1. Company Overview

      • 8.5.2. Key Executives

      • 8.5.3. Company Snapshot

      • 8.5.4. Operating Business Segments

      • 8.5.5. Product Portfolio

      • 8.5.6. Business Performance

      • 8.5.7. Key Strategic Moves and Developments

    • 8.6. Jardiance Ltd.

      • 8.6.1. Company Overview

      • 8.6.2. Key Executives

      • 8.6.3. Company Snapshot

      • 8.6.4. Operating Business Segments

      • 8.6.5. Product Portfolio

      • 8.6.6. Business Performance

      • 8.6.7. Key Strategic Moves and Developments

    • 8.7. Soliqua

      • 8.7.1. Company Overview

      • 8.7.2. Key Executives

      • 8.7.3. Company Snapshot

      • 8.7.4. Operating Business Segments

      • 8.7.5. Product Portfolio

      • 8.7.6. Business Performance

      • 8.7.7. Key Strategic Moves and Developments

    • 8.8. Victoza

      • 8.8.1. Company Overview

      • 8.8.2. Key Executives

      • 8.8.3. Company Snapshot

      • 8.8.4. Operating Business Segments

      • 8.8.5. Product Portfolio

      • 8.8.6. Business Performance

      • 8.8.7. Key Strategic Moves and Developments

    • 8.9. Lantus

      • 8.9.1. Company Overview

      • 8.9.2. Key Executives

      • 8.9.3. Company Snapshot

      • 8.9.4. Operating Business Segments

      • 8.9.5. Product Portfolio

      • 8.9.6. Business Performance

      • 8.9.7. Key Strategic Moves and Developments

    • 8.10. Trulicity

      • 8.10.1. Company Overview

      • 8.10.2. Key Executives

      • 8.10.3. Company Snapshot

      • 8.10.4. Operating Business Segments

      • 8.10.5. Product Portfolio

      • 8.10.6. Business Performance

      • 8.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL AMYLIN ANALOGS MARKET, BY DIABETES TYPE, 2025-2033 ($MILLION)
  • TABLE 2. GLOBAL AMYLIN ANALOGS MARKET FOR TYPE I DIABETES  , BY REGION, 2025-2033 ($MILLION)
  • TABLE 3. GLOBAL AMYLIN ANALOGS MARKET FOR TYPE II DIABETES  , BY REGION, 2025-2033 ($MILLION)
  • TABLE 4. GLOBAL AMYLIN ANALOGS MARKET FOR GESTATIONAL DIABETES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 5. GLOBAL AMYLIN ANALOGS MARKET, BY END USER, 2025-2033 ($MILLION)
  • TABLE 6. GLOBAL AMYLIN ANALOGS MARKET FOR HOSPITALS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 7. GLOBAL AMYLIN ANALOGS MARKET FOR DRUG STORES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 8. GLOBAL AMYLIN ANALOGS MARKET FOR PHARMACY STORES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 9. GLOBAL AMYLIN ANALOGS MARKET FOR ONLINE PHARMACY, BY REGION, 2025-2033 ($MILLION)
  • TABLE 10. GLOBAL AMYLIN ANALOGS MARKET FOR OTHERS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 11. GLOBAL AMYLIN ANALOGS MARKET, BY REGION, 2025-2033 ($MILLION)
  • TABLE 12. NORTH AMERICA AMYLIN ANALOGS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 13. NORTH AMERICA AMYLIN ANALOGS, BY DIABETES TYPE, 2025-2033 ($MILLION)
  • TABLE 14. NORTH AMERICA AMYLIN ANALOGS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 15. U.S. AMYLIN ANALOGS, BY DIABETES TYPE, 2025-2033 ($MILLION)
  • TABLE 16. U.S. AMYLIN ANALOGS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 17. CANADA AMYLIN ANALOGS, BY DIABETES TYPE, 2025-2033 ($MILLION)
  • TABLE 18. CANADA AMYLIN ANALOGS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 19. MEXICO AMYLIN ANALOGS, BY DIABETES TYPE, 2025-2033 ($MILLION)
  • TABLE 20. MEXICO AMYLIN ANALOGS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 21. EUROPE AMYLIN ANALOGS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 22. EUROPE AMYLIN ANALOGS, BY DIABETES TYPE, 2025-2033 ($MILLION)
  • TABLE 23. EUROPE AMYLIN ANALOGS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 24. FRANCE AMYLIN ANALOGS, BY DIABETES TYPE, 2025-2033 ($MILLION)
  • TABLE 25. FRANCE AMYLIN ANALOGS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 26. GERMANY AMYLIN ANALOGS, BY DIABETES TYPE, 2025-2033 ($MILLION)
  • TABLE 27. GERMANY AMYLIN ANALOGS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 28. ITALY AMYLIN ANALOGS, BY DIABETES TYPE, 2025-2033 ($MILLION)
  • TABLE 29. ITALY AMYLIN ANALOGS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 30. SPAIN AMYLIN ANALOGS, BY DIABETES TYPE, 2025-2033 ($MILLION)
  • TABLE 31. SPAIN AMYLIN ANALOGS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 32. UK AMYLIN ANALOGS, BY DIABETES TYPE, 2025-2033 ($MILLION)
  • TABLE 33. UK AMYLIN ANALOGS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 34. RUSSIA AMYLIN ANALOGS, BY DIABETES TYPE, 2025-2033 ($MILLION)
  • TABLE 35. RUSSIA AMYLIN ANALOGS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 36. REST OF EUROPE AMYLIN ANALOGS, BY DIABETES TYPE, 2025-2033 ($MILLION)
  • TABLE 37. REST OF EUROPE AMYLIN ANALOGS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 38. ASIA-PACIFIC AMYLIN ANALOGS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 39. ASIA-PACIFIC AMYLIN ANALOGS, BY DIABETES TYPE, 2025-2033 ($MILLION)
  • TABLE 40. ASIA-PACIFIC AMYLIN ANALOGS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 41. CHINA AMYLIN ANALOGS, BY DIABETES TYPE, 2025-2033 ($MILLION)
  • TABLE 42. CHINA AMYLIN ANALOGS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 43. JAPAN AMYLIN ANALOGS, BY DIABETES TYPE, 2025-2033 ($MILLION)
  • TABLE 44. JAPAN AMYLIN ANALOGS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 45. INDIA AMYLIN ANALOGS, BY DIABETES TYPE, 2025-2033 ($MILLION)
  • TABLE 46. INDIA AMYLIN ANALOGS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 47. SOUTH KOREA AMYLIN ANALOGS, BY DIABETES TYPE, 2025-2033 ($MILLION)
  • TABLE 48. SOUTH KOREA AMYLIN ANALOGS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 49. AUSTRALIA AMYLIN ANALOGS, BY DIABETES TYPE, 2025-2033 ($MILLION)
  • TABLE 50. AUSTRALIA AMYLIN ANALOGS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 51. THAILAND AMYLIN ANALOGS, BY DIABETES TYPE, 2025-2033 ($MILLION)
  • TABLE 52. THAILAND AMYLIN ANALOGS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 53. MALAYSIA AMYLIN ANALOGS, BY DIABETES TYPE, 2025-2033 ($MILLION)
  • TABLE 54. MALAYSIA AMYLIN ANALOGS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 55. INDONESIA AMYLIN ANALOGS, BY DIABETES TYPE, 2025-2033 ($MILLION)
  • TABLE 56. INDONESIA AMYLIN ANALOGS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 57. REST OF ASIA PACIFIC AMYLIN ANALOGS, BY DIABETES TYPE, 2025-2033 ($MILLION)
  • TABLE 58. REST OF ASIA PACIFIC AMYLIN ANALOGS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 59. LAMEA AMYLIN ANALOGS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 60. LAMEA AMYLIN ANALOGS, BY DIABETES TYPE, 2025-2033 ($MILLION)
  • TABLE 61. LAMEA AMYLIN ANALOGS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 62. BRAZIL AMYLIN ANALOGS, BY DIABETES TYPE, 2025-2033 ($MILLION)
  • TABLE 63. BRAZIL AMYLIN ANALOGS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 64. SOUTH AFRICA AMYLIN ANALOGS, BY DIABETES TYPE, 2025-2033 ($MILLION)
  • TABLE 65. SOUTH AFRICA AMYLIN ANALOGS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 66. SAUDI ARABIA AMYLIN ANALOGS, BY DIABETES TYPE, 2025-2033 ($MILLION)
  • TABLE 67. SAUDI ARABIA AMYLIN ANALOGS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 68. UAE AMYLIN ANALOGS, BY DIABETES TYPE, 2025-2033 ($MILLION)
  • TABLE 69. UAE AMYLIN ANALOGS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 70. ARGENTINA AMYLIN ANALOGS, BY DIABETES TYPE, 2025-2033 ($MILLION)
  • TABLE 71. ARGENTINA AMYLIN ANALOGS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 72. REST OF LAMEA AMYLIN ANALOGS, BY DIABETES TYPE, 2025-2033 ($MILLION)
  • TABLE 73. REST OF LAMEA AMYLIN ANALOGS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 74. NOVO NORDISK: KEY EXECUTIVES
  • TABLE 75. NOVO NORDISK: COMPANY SNAPSHOT
  • TABLE 76. NOVO NORDISK: OPERATING SEGMENTS
  • TABLE 77. NOVO NORDISK: PRODUCT PORTFOLIO
  • TABLE 78. NOVO NORDISK: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 79. SANOFI: KEY EXECUTIVES
  • TABLE 80. SANOFI: COMPANY SNAPSHOT
  • TABLE 81. SANOFI: OPERATING SEGMENTS
  • TABLE 82. SANOFI: PRODUCT PORTFOLIO
  • TABLE 83. SANOFI: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 84. ASTRAZENECA: KEY EXECUTIVES
  • TABLE 85. ASTRAZENECA: COMPANY SNAPSHOT
  • TABLE 86. ASTRAZENECA: OPERATING SEGMENTS
  • TABLE 87. ASTRAZENECA: PRODUCT PORTFOLIO
  • TABLE 88. ASTRAZENECA: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 89. BOEHRINGER INGELHEIM: KEY EXECUTIVES
  • TABLE 90. BOEHRINGER INGELHEIM: COMPANY SNAPSHOT
  • TABLE 91. BOEHRINGER INGELHEIM: OPERATING SEGMENTS
  • TABLE 92. BOEHRINGER INGELHEIM: PRODUCT PORTFOLIO
  • TABLE 93. BOEHRINGER INGELHEIM: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 94. ELI LILLY AND COMPANY: KEY EXECUTIVES
  • TABLE 95. ELI LILLY AND COMPANY: COMPANY SNAPSHOT
  • TABLE 96. ELI LILLY AND COMPANY: OPERATING SEGMENTS
  • TABLE 97. ELI LILLY AND COMPANY: PRODUCT PORTFOLIO
  • TABLE 98. ELI LILLY AND COMPANY: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 99. JARDIANCE LTD.: KEY EXECUTIVES
  • TABLE 100. JARDIANCE LTD.: COMPANY SNAPSHOT
  • TABLE 101. JARDIANCE LTD.: OPERATING SEGMENTS
  • TABLE 102. JARDIANCE LTD.: PRODUCT PORTFOLIO
  • TABLE 103. JARDIANCE LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 104. SOLIQUA: KEY EXECUTIVES
  • TABLE 105. SOLIQUA: COMPANY SNAPSHOT
  • TABLE 106. SOLIQUA: OPERATING SEGMENTS
  • TABLE 107. SOLIQUA: PRODUCT PORTFOLIO
  • TABLE 108. SOLIQUA: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 109. VICTOZA: KEY EXECUTIVES
  • TABLE 110. VICTOZA: COMPANY SNAPSHOT
  • TABLE 111. VICTOZA: OPERATING SEGMENTS
  • TABLE 112. VICTOZA: PRODUCT PORTFOLIO
  • TABLE 113. VICTOZA: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 114. LANTUS: KEY EXECUTIVES
  • TABLE 115. LANTUS: COMPANY SNAPSHOT
  • TABLE 116. LANTUS: OPERATING SEGMENTS
  • TABLE 117. LANTUS: PRODUCT PORTFOLIO
  • TABLE 118. LANTUS: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 119. TRULICITY: KEY EXECUTIVES
  • TABLE 120. TRULICITY: COMPANY SNAPSHOT
  • TABLE 121. TRULICITY: OPERATING SEGMENTS
  • TABLE 122. TRULICITY: PRODUCT PORTFOLIO
  • TABLE 123. TRULICITY: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL AMYLIN ANALOGS MARKET SEGMENTATION
  • FIGURE 2. GLOBAL AMYLIN ANALOGS MARKET
  • FIGURE 3. SEGMENTATION AMYLIN ANALOGS MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN AMYLIN ANALOGS MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALAMYLIN ANALOGS MARKET
  • FIGURE 11. AMYLIN ANALOGS MARKET SEGMENTATION, BY BY DIABETES TYPE
  • FIGURE 12. AMYLIN ANALOGS MARKET FOR TYPE I DIABETES  , BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 13. AMYLIN ANALOGS MARKET FOR TYPE II DIABETES  , BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 14. AMYLIN ANALOGS MARKET FOR GESTATIONAL DIABETES, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 15. AMYLIN ANALOGS MARKET SEGMENTATION, BY BY END USER
  • FIGURE 16. AMYLIN ANALOGS MARKET FOR HOSPITALS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 17. AMYLIN ANALOGS MARKET FOR DRUG STORES, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 18. AMYLIN ANALOGS MARKET FOR PHARMACY STORES, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 19. AMYLIN ANALOGS MARKET FOR ONLINE PHARMACY, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 20. AMYLIN ANALOGS MARKET FOR OTHERS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 21. TOP WINNING STRATEGIES, BY YEAR, 2022-2024*
  • FIGURE 22. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2022-2024*
  • FIGURE 23. TOP WINNING STRATEGIES, BY COMPANY, 2022-2024*
  • FIGURE 24. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 25. COMPETITIVE DASHBOARD
  • FIGURE 26. COMPETITIVE HEATMAP: AMYLIN ANALOGS MARKET
  • FIGURE 27. TOP PLAYER POSITIONING, 2024
  • FIGURE 28. NOVO NORDISK: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 29. NOVO NORDISK: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 30. NOVO NORDISK: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 31. SANOFI: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 32. SANOFI: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 33. SANOFI: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 34. ASTRAZENECA: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 35. ASTRAZENECA: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 36. ASTRAZENECA: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 37. BOEHRINGER INGELHEIM: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 38. BOEHRINGER INGELHEIM: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 39. BOEHRINGER INGELHEIM: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 40. ELI LILLY AND COMPANY: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 41. ELI LILLY AND COMPANY: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 42. ELI LILLY AND COMPANY: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 43. JARDIANCE LTD.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 44. JARDIANCE LTD.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 45. JARDIANCE LTD.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 46. SOLIQUA: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 47. SOLIQUA: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 48. SOLIQUA: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 49. VICTOZA: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 50. VICTOZA: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 51. VICTOZA: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 52. LANTUS: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 53. LANTUS: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 54. LANTUS: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 55. TRULICITY: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 56. TRULICITY: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 57. TRULICITY: REVENUE SHARE, BY REGION, 2024 (%)

Purchase Full Report of
Amylin Analogs Market

PURCHASE OPTIONS



* Taxes/Fees, If applicable will be added during checkout. All prices in USD.

Have a question ?

Need to add more ?

Avail up to 30% discount on subscription plans on


Avenue

© 2025 Allied Market Research. All Rights Reserved